Abstract
A TECHNIQUE which has proved highly successful in the isolation and identification of pharmacological receptors, is the use of a high affinity, selective label which binds irreversibly to the receptor1. We report here our findings with a new irreversible, potent and cardioselective (β-1) β adrenoceptor antagonist, chloropractolol (I). This new compound is a modification (Fig. 1) of practolol (II), and represents the first known selective, irreversible β antagonist. Chloropractolol (I) was prepared with the intention of incorporating an alkylating function into the parent compound, while maintaining β-1 selectivity. An additional advantage of using practolol (II) rather than propranolol as the parent molecule, is that the resultant compound should, like practolol, lack nonspecific membrane stabilising effect2 and any interaction with 5-hydroxytryptamine receptors 3.
Original language | English |
---|---|
Pages (from-to) | 635-636 |
Number of pages | 2 |
Journal | Nature |
Volume | 255 |
Issue number | 5510 |
DOIs | |
State | Published - 1975 |
Externally published | Yes |